Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Same author

Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.

medRxiv : the preprint server for health sciences·2026

Same author

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.

Lancet (London, England)·2026

Same author

Elevated functional magnetic resonance imaging activity in cognitively normal participants predicts future dementia.

Brain communications·2026

Same author

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease.

JAMA neurology·2026

Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 24, 2026

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

Biomarkers.

Andreia Rocha¹, Bruna Bellaver¹, Carolina Soares¹

¹University of Pittsburgh, Pittsburgh, PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association

|January 22, 2026

Summary

This summary is machine-generated.

Four tau PET tracers show variable Braak staging in Alzheimer's disease (AD). While tracers offer similar average stages, individual case staging may differ, impacting clinical use.

More Related Videos

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Related Experiment Videos

Last Updated: Jan 24, 2026

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Area of Science:

Neuroimaging
Neuropathology

Background:

Alzheimer's disease (AD) Braak staging classifies tau pathology using post-mortem exams.
Adapting Braak staging to PET imaging is challenging due to tracer differences.
This study compares four tau PET tracers: Flortaucipir, MK6240, PI2620, and RO948.

Purpose of the Study:

Compare Braak staging across four tau PET tracers.
Evaluate tracer agreement and systematic bias in staging tau pathology.
Model tau PET Braak region trajectories based on amyloid-beta (Aβ) burden.

Main Methods:

Assessed 90 participants (cognitively unimpaired, MCI, dementia) using Aβ PET and four tau PET tracers.
Defined Braak positivity using Aβ-negative cognitively unimpaired individuals.
Employed Bland-Altman analysis and Lowess modeling to assess tracer agreement and trajectories.

Main Results:

Tau PET Braak staging trajectories varied significantly by tracer and Aβ burden.
Earliest abnormal regions differed: Braak I for MK6240, RO948, PI2620; Braak IV for Flortaucipir.
Tracer agreement was highest at Braak 0 and Braak IV-V (approx. 70%), with low concordance in intermediate stages.

Conclusions:

Discrepancies exist in Braak staging among Flortaucipir, MK6240, PI2620, and RO948.
While tracers show comparable average stages, they are not fully interchangeable for individual patient staging.
Further research is needed to refine tau PET staging in Alzheimer's disease.